Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9226MR)

This product GTTS-WQ9226MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ9226MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15839MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ14854MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ6652MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ15239MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TAK-079
GTTS-WQ5290MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD124
GTTS-WQ15827MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ1129MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-927
GTTS-WQ5526MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP4940
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW